In the last trading session, 1,090,629 CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 2.28. With the company’s per share price at $144.33 changed hands at -$0.48 or 0% during last session, the market valuation stood at $11.59 Billion. CRSP’s last price was a discount, traded about -52.57% off its 52-week high of $220.2. The share price had its 52-week low at $76.71, which suggests the last value was 46.85% up since then. When we look at CRISPR Therapeutics AG’s average trading volume, we note the 10-day average is 1.32 Million shares, with the 3-month average coming to 1.46 Million.

>> 7 Top Picks for the Post-Pandemic Economy

Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Overweight, calculated at a mean rating of 2.1. If we narrow down to specifics, the data shows that 1 out of 21 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 6 recommended CRSP as a Hold, 14 felt it is a Buy and none rated the stock as Underweight. CRISPR Therapeutics AG’s EPS for the current quarter is expected to be $3.52.

Although CRSP has turned red as seen at the end of in last trading. With action -0.33%, the performance over the past five days has been red. The jump to weekly highs of $158.2 on Friday, Jul 02 added 8.8% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.06%, with the 5-day performance at -0.08% in the red. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 0.2% up. Looking at the short shares, we see there were 3.36 Million shares sold at short interest cover period of 2.3 days.

The consensus price target for the stock as assigned by Wall Street analysts is $163.11, meaning bulls need an upside of 13.01% from its current market value. According to analyst projections, CRSP’s forecast low is $117 with $220 as the target high. To hit the forecast high, the stock’s price needs a +52.43% upsurge from its current level, while the stock would need to tank -18.94% for it to hit the projected low.

CRISPR Therapeutics AG (CRSP) estimates and forecasts

Data shows that the CRISPR Therapeutics AG share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -25.77% over the past 6 months, a 112.48% in annual growth rate that is considerably higher than the industry average of 8.8%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for CRISPR Therapeutics AG will rise +370.8%, while the growth in revenue is estimated to hit 20.5% for the next quarter. Year-over-year growth is forecast to reach 64633% up from the last financial year.

Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of $420.92 Million. 15 analysts are of the opinion that CRISPR Therapeutics AG’s revenue for the quarter ending September 01, 2021 will be $61.05 Million. The company’s revenue for the corresponding quarters a year ago was $18.12 Million and $148Million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 2223%. The estimates for the next quarter sales put growth at 41150%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -52.5%. The 2021 estimates are for CRISPR Therapeutics AG earnings to decrease by -550.5%, but the outlook for the next 5-year period is at 0% per year.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!


CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 12.96% of CRISPR Therapeutics AG shares while 58.56% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 67.28%. There are 576 institutions holding the CRISPR Therapeutics AG stock share, with ARK Investment Management, LLC the top institutional holder. As of Mar 30, 2021, the company held 10.94% of the shares, roughly 8.29 Million CRSP shares worth $1.01 Billion.

Capital International Investors holds the second largest percentage of outstanding shares, with 6.43% or 4.87 Million shares worth $593.25 Million as of Mar 30, 2021.

>> 7 Top Picks for the Post-Pandemic Economy

Among Mutual Funds, the top two as of May 30, 2021 were ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. With 4895771 shares estimated at $578.58 Million under it, the former controlled 6.46% of total outstanding shares. On the other hand, New Perspective Fund Inc held about 2.77% of the shares, roughly 2.1 Million shares worth around $255.64 Million.

Source link